BD Diagnostics Gets FDA Clearance for Second BD Max Staph Assay | GenomeWeb

NEW YORK (GenomeWeb News) — BD Diagnostics, a segment of Becton Dickinson, said today that it has received US Food and Drug Administration clearance to market its BD Max MRSA XT assay for use on the BD Max system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.